drugset / Trial / NCT06918080

Hepatoprotective Measures for Children at High Risk of NAFLD

NCT06918080

Phase 4 Active not recruiting 200 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelPrevention

Summary

Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure. In childhood, it may be associated with a metabolic syndrome or with obesity, or even in normal children. Liver biopsy has always been the gold standard method for diagnosing and staging NAFLD. However, the urge of non-invasive biomarkers or imaging techniques has been recommended. This study will evaluate the use of the LIVERFASt biomarkers for early detection and staging of NAFLD.

Timeline

Start
2023-11-19
Primary completion
2025-05
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 20 mg/kg Oral